Source: Annual Congress 2007 - New insight into the pathophysiology of asthma
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
F. Krouwels (Amsterdam, Netherlands). Implementation of NO measurement in the daily practice leads to more confident astma diagnosis and has important effects on anti-inflammatory treatment. Eur Respir J 2007; 30: Suppl. 51, 3302

Member's Comments

No comment yet.

Related content which might interest you: Early detection of asthma exacerbations and the use of action points for treatment decisions in self-management plans Source: Annual Congress 2011 - Monitoring exacerbations of airway diseases Year: 2011 SABINA: global programme to evaluate prescriptions and clinical outcomes related to short-acting ß2-agonist use in asthma Source: Eur Respir J, 55 (2) 1901858; 10.1183/13993003.01858-2019 Year: 2020 The use of an asthma diary in the treatment of astmatics in general practice; an evaluation on the first three years after implementation Source: Eur Respir J 2002; 20: Suppl. 38, 53s Year: 2002 A new observer independent method to assess therapy response in children with severe asthma based on daily lung function Source: Annual Congress 2013 –Uncontrolled and severe asthma in children Year: 2013 Predictors of effectiveness of omalizumab treatment in patients with severe asthma recruited in a real-life setting Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015 Development and evaluation of an educational intervention targeted at optimising adherence with measures to prevent asthma in children with a familial allergic disposition (FOCUS-project) Source: Eur Respir J 2002; 20: Suppl. 38, 329s Year: 2002 Time to ban short-acting ß-agonists and use anti-inflammatory treatment as required to improve outcomes Source: Virtual Congress 2021 – Wheezing illnesses along the life span Year: 2021 When biology meets behaviour: can medication adherence mask the contribution of pharmacogenetic effects in asthma? Source: Eur Respir J, 58 (3) 2100304; 10.1183/13993003.00304-2021 Year: 2021 Assessing the effect of medical therapy in COPD: from pathophysiology and biomarkers to clinical practice Source: Annual Congress 2009 - PG15 The complexity of COPD: assessment and advanced therapies Year: 2009 Is there a place for anti-remodelling drugs in asthma which may not display immediate clinical efficacy? Source: Eur Respir J 2004; 24: 1-2 Year: 2004 How can we improve asthma management? Source: Annual Congress 2005 - Asthma management - important issues Year: 2005 Efficient and practical management for checking inhalation technique and discussing medication adherence before treatment step-up in uncontrolled asthma Source: International Congress 2018 – Asthma: clinical screening tools Year: 2018 Physicians judge add-on omalizumab therapy as an effective treatment for patients with severe persistent allergic asthma: a pooled analysis Source: Eur Respir J 2005; 26: Suppl. 49, 49s Year: 2005 What is the optimal management option for occupational asthma? Source: Eur Respir Rev 2012; 21: 97-104 Year: 2012 Suppression of FENO with observed inhaled corticosteroid therapy in severe asthma: is it a useful test in clinical practice? Source: ERJ Open Res, 5 (4) 00123-2019; 10.1183/23120541.00123-2019 Year: 2019 Clinical management: recommended practice including the place of antibiotics Source: Annual Congress 2007 - PG24 - GRACE full-day course. From cough to asthma: the role of infection Year: 2007 The patient’s role in the choice of new inhaler devices and dosing regimens for asthma and COPD: A preference study Source: International Congress 2016 – Kaleidoscope of respiratory nursing Year: 2016 Less is more: the impact of maintenance treatment adherence in severe asthma clinical trials Source: Eur Respir J, 53 (5) 1900599; 10.1183/13993003.00599-2019 Year: 2019 A digital therapy for proactively managing exacerbations and delivering therapeutic benefit to patients with moderate to severe asthma Source: International Congress 2019 – Clinical approach to asthma management Year: 2019 Development of a tool to measure the clinical response to biologic therapy in uncontrolled severe asthma: the FEOS score. Source: Virtual Congress 2021 – Severe asthma: evaluation using patient-reported outcome measures (PROMs) and biomarkers, comorbidities and treatments Year: 2021